A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.
about
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancerPatient-derived tumour xenografts as models for oncology drug developmentPatient-derived xenograft models of colorectal cancer in pre-clinical research: a systematic reviewAdvances in targeted and immunobased therapies for colorectal cancer in the genomic eraBiomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRASPharmacologic resistance in colorectal cancer: a reviewAn Integrative Approach to Precision Cancer Medicine Using Patient-Derived XenograftsThe Insulin/IGF System in Colorectal Cancer Development and Resistance to TherapyCurrent State of Animal (Mouse) Modeling in Melanoma ResearchRole of HER2 in NSCLCMolecular phenotypes of colorectal cancer and potential clinical applicationsNew findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?Personalized treatment for advanced colorectal cancer: KRAS and beyondMolecular therapy of colorectal cancer: progress and future directionsIn vitro and in vivo models for analysis of resistance to anticancer molecular therapiesPrimary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategiesAcquired resistance to EGFR-targeted therapies in colorectal cancerOne mouse, one patient paradigm: New avatars of personalized cancer therapyProspects and pitfalls of personalizing therapies for sarcomas: from children, adolescents, and young adults to the elderlySignaling cross-talk in the resistance to HER family receptor targeted therapyCIViC databaseHER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients.A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer.HER2 activating mutations are targets for colorectal cancer treatmentBeyond RAS and BRAF: a target rich disease that is ripe for pickingPatient-derived xenografts: a relevant preclinical model for drug developmentA perspective on anti-EGFR therapies targeting triple-negative breast cancerTherapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidenceMechanisms of resistance to anti-EGFR therapy in colorectal cancerMechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancerOncogenic fingerprint of epidermal growth factor receptor pathway and emerging epidermal growth factor receptor blockade resistance in colorectal cancerGenetically engineered mouse models in oncology research and cancer medicineKRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapyFrom bench to bedside: lessons learned in translating preclinical studies in cancer drug developmentCytohesins/ARNO: the function in colorectal cancer cellsCancer Stem Cell-Based Models of Colorectal Cancer Reveal Molecular Determinants of Therapy Resistance.The future of patient-derived tumor xenografts in cancer treatment.ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal CancerHER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression
P2860
Q24563539-F4A2FF12-1DC5-4189-8B0F-53BADC84F055Q24604068-90EA72B8-A631-492F-AFE4-59CE5D0D8C26Q26741651-54199D6D-0351-44F7-98C0-EBDB5FA4D2F6Q26751344-7398AF23-0DB4-44D2-9C37-ECA44360DAC8Q26766535-78CF1F95-35DD-432F-BB87-7EBCBE74FFF5Q26769850-1F996BD8-BCCF-4995-8C88-6AB90A2BB961Q26772895-D66F016F-1E3C-4FA4-AC81-C852FC8A86E2Q26777125-73F7ED65-13C9-45D0-9708-885EFDC53738Q26781652-79590715-A712-4B8A-9A6F-8D58030EE15FQ26781683-191DFC6C-D7D8-4B8E-AE94-2846480EC983Q26785725-72579987-E33D-45EB-8737-0AB5DCF2BF0CQ26796348-980BC812-AED8-4BA6-8509-F17050D85E1AQ26822817-E61C2657-2881-4825-8C1F-3C5810827DA1Q27005764-BCE49C10-E21C-448A-9AF6-0B2076301349Q27014174-83A1E0A3-1755-4C0F-86BA-948AC5819F1AQ27015224-B82C9893-1566-4D12-8E36-0300404E6116Q27022741-29CD5441-19EA-4285-81C7-130C2B2BE1B8Q27023342-4223A04C-727F-4A4D-800A-A31E34683858Q27025344-8836B8B7-8ADB-4EB8-87E6-10E4AAC41FD2Q27027778-4D627F96-C406-4493-B4A2-2EC734321D7CQ27612411-85AB68FB-6CA9-41D7-9DD9-0ACC22FCD3CAQ27852057-04E8AF36-FF70-4D3C-9E3F-47371E640C54Q27853184-8C0A05EF-B3B1-4218-8DDF-9C5D60980D3DQ27853193-A724C117-0FC6-482F-95D8-179A9EA390AEQ28066095-16153671-6E13-4F86-B131-98959C023316Q28067191-4967D059-7FBE-418D-A8AD-3E106D0B2DB6Q28069867-F009F3E4-5DF0-4330-9DCB-7FA30D874C6AQ28071772-9D74C992-2655-48BA-B8AA-631D6CEB566DQ28074073-63868D56-012F-4D7A-B467-722D8CB45F53Q28076490-ED95E5D3-94E7-4FC8-90A8-0063C8C67FADQ28077545-ACF81736-D5B1-437A-BD6F-B8F828A4C226Q28079323-24445393-7416-45E2-9C23-AF2601940C14Q28285473-14D102BD-D1A7-42A2-85C4-6892DF06924AQ28533949-4612CBDA-7104-44E7-9F33-CF1EA86F5C6EQ28540770-848DB77F-F122-4F9E-B3E3-586F7EAF8544Q30729579-C11EA8C1-5290-4000-9229-E6B4C046ED25Q33361578-A16BAF1F-DC49-4FAE-9DFC-CB285605F255Q33601653-5098D3CF-9A54-4F6D-9024-8F003E033EE0Q33624491-3F8BCD74-9B6B-4D34-8286-5CE053268838Q33690070-C6B311A7-BD86-4697-96FE-3CD69BB2B08C
P2860
A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.
description
2011 nî lūn-bûn
@nan
2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A molecularly annotated platfo ...... b-resistant colorectal cancer.
@ast
A molecularly annotated platfo ...... b-resistant colorectal cancer.
@en
A molecularly annotated platfo ...... b-resistant colorectal cancer.
@nl
type
label
A molecularly annotated platfo ...... b-resistant colorectal cancer.
@ast
A molecularly annotated platfo ...... b-resistant colorectal cancer.
@en
A molecularly annotated platfo ...... b-resistant colorectal cancer.
@nl
prefLabel
A molecularly annotated platfo ...... b-resistant colorectal cancer.
@ast
A molecularly annotated platfo ...... b-resistant colorectal cancer.
@en
A molecularly annotated platfo ...... b-resistant colorectal cancer.
@nl
P2093
P50
P921
P3181
P1433
P1476
A molecularly annotated platfo ...... b-resistant colorectal cancer.
@en
P2093
Alberto Pisacane
Andrea Muratore
Dario Ribero
Davide Corà
Davide Torti
Francesco Galimi
Francesco Sassi
Giorgia Migliardi
Livio Trusolino
Lorenzo Capussotti
P304
P3181
P356
10.1158/2159-8290.CD-11-0109
P50
P577
2011-11-01T00:00:00Z